There was no significant difference in the number of CD16/CD56 double-positive NK cells which can contribute to ADCC of mogamulizumab, before treatment initiation between ATL and PTCL patients, or between these patients and healthy adult volunteers (Fig. 1b). Here, NCAM1 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.